Categories AlphaGraphs, Earnings

Strong airplane deliveries lift Boeing’s first quarter results

Boeing (BA) reported better-than-expected first quarter results before the opening bell today. Revenue and adjusted earnings for the quarter topped analyst consensus. Adjusted earnings shot up 68% to $3.64 per share, while revenue came in at $23.38 billion, up 6% compared to prior year period.

The aircraft maker saw solid growth across all its segments during the quarter. Profits jumped 57% to $2.47 billion primarily due to improved airplane deliveries to its customers and $200 million savings due to the recent income tax reforms. Backlogs improved $11 billion to $486 billion at the end of quarter, compared to the previous quarter.

Commercial Airplanes segment, which brings in a lion’s share of revenues, hogged the limelight during the quarter. Operating profit saw 73% growth, primarily due to productivity improvements resulting in more deliveries. Order backlogs remained healthy at 5,800 airplanes worth $415 billion. The company expects to ramp up its production to deliver 900 planes per year by 2020. This is expected to bump up profits in the upcoming quarters.

Boeing Q1 2018 Earnings

Defense segment earnings grew 18% and backlogs decreased $13 billion to $50 billion compared to the prior year. KC-46 tanker program saw progress in the quarter completing the on-load certification testing. The tanker program has hurt the company due to technical issues and bloated costs. Global services’ division profits rose modestly to 3% on $3.9 billion sales, aided by the commercial services.

Boeing revised its 2018 outlook aided by strong macro factors. The aerospace giant now expects its adjusted EPS to be between $14.30 and $14.50, compared to $13.80 and $14.00 reported earlier. Operating cash flow is now expected to be between $15 billion and $15.5 billion.

Shares price rose 2.7% when the markets opened at $338.1.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top